Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy

被引:8
|
作者
Rubio-Briones, J. [1 ]
Iborra, I. [1 ]
Trassierra, M. [1 ]
Collado, A. [1 ]
Casanova, J. [1 ]
Gomez-Ferrer, A. [1 ]
Ricos, J. V. [1 ]
Monros, J. L. [1 ]
Dumont, R. [1 ]
Solsona, E. [1 ]
机构
[1] Inst Valenciano Oncol, Serv Urol, Valencia, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2010年 / 34卷 / 07期
关键词
Death; Gleason score; Metastases; Prediction; Prostate cancer; PSA; Radical prostatectomy; Risk groups; Treatment failure; LONG-TERM SURVIVAL; RADIATION-THERAPY; MEN; RADIOTHERAPY; OUTCOMES; DISEASE; STAGE;
D O I
10.1016/j.acuro.2010.03.029
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To determine our results in high risk (HR) prostate cancer (PCa) patients treated with radical prostatectomy (RP) and to establish preoperative prognosis factors. Material and methods: Retrospective study of 925 RP. Mean follow-up for the HR group was 89.8+/-53.6 months. Following NCCN criteria, we operated 210 (22.7%) HR and 715 (77.3%) low/intermediate risk patients. End point was metastatic progression. Kaplan-Meier method for survival comparison among groups and Cox regression model for multivariate analysis of preoperative prognostic factors were used. Results: Revised period; 1986-2007. Fifty-four patients (25.7%) were free of disease and 8 patients (3.8%) died for other causes free of disease. Disease progressed in 148 patients (70.5%); death due to tumour progression occurred in 42 cases (20%) and due to other causes in 25 patients (11.9%). Seventy-nine patients in HR group (38%) vs 549 low/intermediate risk group (78.5%) did not deserve further treatments (p<0.001). The uni and multivariate analysis for metastatic progression showed both Gleason score at biopsy (RR=1.922; 95% CI 1.106-3.341, p=0.020) and clinical stage (RR=2.290; 95% CI 1.269-4.133, p=0.006) showed independent prognostic value for metastatic progression, but not PSA. Conclusions: A HR patient can be cured in a third of the cases and will need multimodal treatments in more than half of the times. We prompt surgery in a young healthy patient with a resectable tumour, mainly if just one bad prognostic factor is present and defiantly if this is just PSA elevation. (C) 2010 AEU. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:610 / 617
页数:8
相关论文
共 50 条
  • [1] Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy
    Yossepowitch, Ofer
    Eggener, Scott E.
    Serio, Angel M.
    Caruer, Brett S.
    Bianco, Fernando J., Jr.
    Scardino, Peter T.
    Eastham, James A.
    [J]. EUROPEAN UROLOGY, 2008, 53 (05) : 950 - 959
  • [2] The association of type and number of high-risk criteria with cancer-specific mortality in prostate cancer patients treated with radical prostatectomy
    Chierigo, Francesco
    Flammia, Rocco Simone
    Sorce, Gabriele
    Hoeh, Benedikt
    Hohenhorst, Lukas
    Panunzio, Andrea
    Tian, Zhe
    Saad, Fred
    Graefen, Marcus
    Gallucci, Michele
    Briganti, Alberto
    Montorsi, Francesco
    Chun, Felix K. H.
    Shariat, Shahrokh F.
    Antonelli, Alessandro
    Guano, Giovanni
    Mantica, Guglielmo
    Borghesi, Marco
    Suardi, Nazareno
    Terrone, Carlo
    Karakiewicz, Pierre I.
    [J]. CURRENT UROLOGY, 2024, 18 (02) : 128 - 132
  • [3] Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy
    Kobayashi, Takashi
    Kimura, Takahiro
    Lee, Chunwoo
    Inoue, Takahiro
    Terada, Naoki
    Kono, Yuka
    Kamba, Tomomi
    Kim, Choung-Soo
    Egawa, Shin
    Ogawa, Osamu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (08) : 762 - 767
  • [4] The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Brachytherapy
    Wattson, D. A.
    Chen, M.
    Moul, J. W.
    Moran, B. J.
    Dosoretz, D. E.
    Robertson, C. N.
    Polascik, T. J.
    Braccioforte, M. H.
    Salenius, S. A.
    D'Amico, A. V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S434 - S434
  • [5] Association of SPARC expression with metastatic progression and prostate cancer-specific mortality after radical prostatectomy
    Jeldres, Claudio
    Johnston, Richard Bruce
    Porter, Christopher R.
    Nelson, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy
    Boehm, Katharina
    Leyh-Bannurah, Sami-Ramzi
    Rosenbaum, Clemens
    Brandi, Laurenz S.
    Budaeus, Lars
    Graefen, Markus
    Huland, Hartwig
    Haferkamp, Axel
    Tilki, Derya
    [J]. BJU INTERNATIONAL, 2017, 120 (05) : 666 - 672
  • [7] A Competing Risk Analysis of Cancer-Specific Mortality of Initial Treatment with Radical Prostatectomy versus Radiation Therapy in Clinically Localized High-Risk Prostate Cancer
    Lee, Joo Yong
    Cho, Kang Su
    Kwon, Jong Kyou
    Jeh, Seong Uk
    Kang, Ho Won
    Diaz, Richilda Red
    Ham, Won Sik
    Koom, Woong Sub
    Keum, Ki Chang
    Choi, Young Deuk
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (12) : 4026 - 4033
  • [8] SPARC EXPRESSION IS ASSOCIATED WITH METASTATIC PROGRESSION AND PROSTATE CANCER-SPECIFIC MORTALITY AFTER RADICAL PROSTATECTOMY
    Jeldres, Claudio
    Johnston, Richard
    Porter, Christopher
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E324 - E324
  • [9] A Competing Risk Analysis of Cancer-Specific Mortality of Initial Treatment with Radical Prostatectomy versus Radiation Therapy in Clinically Localized High-Risk Prostate Cancer
    Joo Yong Lee
    Kang Su Cho
    Jong Kyou Kwon
    Seong Uk Jeh
    Ho Won Kang
    Richilda Red Diaz
    Won Sik Ham
    Woong Sub Koom
    Ki Chang Keum
    Young Deuk Choi
    [J]. Annals of Surgical Oncology, 2014, 21 : 4026 - 4033
  • [10] Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients
    Benedikt Hoeh
    Jan L. Hohenhorst
    Rocco Flammia
    Benedikt Horlemann
    Gabriele Sorce
    Francesco Chierigo
    Zhe Tian
    Fred Saad
    Markus Graefen
    Michele Gallucci
    Alberto Briganti
    Carlo Terrone
    Shahrokh F. Shariat
    Luis A. Kluth
    Andreas Becker
    Felix K. H. Chun
    Pierre I. Karakiewicz
    [J]. International Urology and Nephrology, 2022, 54 : 81 - 87